Front. Pharmacol.
Frontiers in Pharmacology
Front. Pharmacol.
1663-9812
Frontiers Media S.A.
10.3389/fphar.2016.00468
Pharmacology
Correction
Corrigendum: Pazopanib in Metastatic Renal Cancer: A “Real-World” Experience at National Cancer Institute “Fondazione G. Pascale”
Cecere Sabrina C.
1
Rossetti Sabrina
1
Cavaliere Carla
2
Della Pepa Chiara
1
Di Napoli Marilena
1
Crispo Anna
3
Iovane Gelsomina
1
Piscitelli Raffaele
4
Sorrentino Domenico
5
Ciliberto Gennaro
6
Maiolino Piera
4
Muto Paolo
7
Perdonà Sisto
5
Berretta Massimiliano
8
Pignata Sandro
1
Facchini Gaetano
1
*
D'Aniello Carmine
9
1Division of Medical Oncology, Department of Uro-Gynaecological Oncology, Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale,” Naples, Italy
2Department of Onco-Ematology Medical Oncology, S.G. Moscati Hospital of Taranto Taranto, Italy
3Unit of Epidemiology, Struttura Complessa di Statistica Medica, Biometria e Bioinformatica, Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale,” Naples, Italy
4Pharmacy Unit, Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale,” Naples, Italy
5Division of Urology, Department of Uro-Gynaecological Oncology, Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale,” Naples, Italy
6Scientific Direction, Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale,” Naples, Italy
7Division of Radiation Oncology, Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale,” Naples, Italy
8Division of Medical Oncology–Centro di Riferimento Oncologico Aviano, Italy
9Oncology Unit, A.O.R.N. dei COLLI “Ospedali Monaldi-Cotugno-CTO,” Naples, Italy
Edited and reviewed by: Giovanni Li Volti, University of Catania, Italy
*Correspondence: Gaetano Facchini gafacchi@libero.it
This article was submitted to Experimental Pharmacology and Drug Discovery, a section of the journal Frontiers in Pharmacology
05
12
2016
2016
7
468
10
10
2016
18
11
2016
Copyright © 2016 Cecere, Rossetti, Cavaliere, Della Pepa, Di Napoli, Crispo, Iovane, Piscitelli, Sorrentino, Ciliberto, Maiolino, Muto, Perdonà, Berretta, Pignata, Facchini and D'Aniello.
2016
Cecere, Rossetti, Cavaliere, Della Pepa, Di Napoli, Crispo, Iovane, Piscitelli, Sorrentino, Ciliberto, Maiolino, Muto, Perdonà, Berretta, Pignata, Facchini and D'Aniello
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
A corrigendum on Pazopanib in Metastatic Renal Cancer: A “Real-World” Experience at National Cancer Institute “Fondazione G. Pascale” by Cecere, S. C., Rossetti, S., Cavaliere, C., Della Pepa, C., Di Napoli, M., Crispo, A., et al. (2016). Front. Pharmacol. 7:287. doi: 10.3389/fphar.2016.00287
pazopanib
metastatic renal cancer
real world
angiogenesis inhibitors
treatment
In the original article, we have neglected to thank our funder, Novartis Farma S.p.A. The Funding Statement appears below.
Funding
Novartis Farma S.p.A. supported publication of this article.
The authors apologize for this oversight. This error does not change the scientific conclusions of the article in any way.
Conflict of interest statement
The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.